Can we predict who needs extra therapy after kidney cancer surgery?

NCT ID NCT07753343

Recruiting now Knowledge-focused Sponsor: University Hospital, Bordeaux Source: ClinicalTrials.gov ↗

First seen Aug 07, 2026 · Last updated Aug 07, 2026

Summary

This study analyzes data from over 6,000 French patients with non-metastatic kidney cancer to understand how the disease progresses after surgery. The goal is to identify which patients are at high risk of recurrence and might benefit from adjuvant immunotherapy, while avoiding unnecessary treatment for others. By examining real-world outcomes, the study aims to refine treatment decisions and potentially reduce healthcare costs.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: This research could help doctors better identify which kidney cancer patients are most likely to benefit from adjuvant immunotherapy after surgery, potentially sparing others from unnecessary side effects and costs.
What could go wrong: As an observational study, it cannot prove cause and effect. The findings depend on the accuracy and completeness of registry data, and may not apply to all patient populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RENAL CELL CARCINOMA

Contacts and locations

Locations

CHU Bordeaux
RECRUITING

Bordeaux, 33000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.